Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Research & Development: 2016-2024

Historic Research & Development for Rhythm Pharmaceuticals (RYTM) over the last 8 years, with Dec 2024 value amounting to $238.0 million.

  • Rhythm Pharmaceuticals' Research & Development rose 21.34% to $46.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $166.5 million, marking a year-over-year decrease of 26.56%. This contributed to the annual value of $238.0 million for FY2024, which is 76.33% up from last year.
  • Per Rhythm Pharmaceuticals' latest filing, its Research & Development stood at $238.0 million for FY2024, which was up 76.33% from $135.0 million recorded in FY2023.
  • Rhythm Pharmaceuticals' 5-year Research & Development high stood at $238.0 million for FY2024, and its period low was $104.1 million during FY2021.
  • Moreover, its 3-year median value for Research & Development was $135.0 million (2023), whereas its average is $160.5 million.
  • Data for Rhythm Pharmaceuticals' Research & Development shows a peak YoY spiked of 76.33% (in 2024) over the last 5 years.
  • Over the past 4 years, Rhythm Pharmaceuticals' Research & Development (Yearly) stood at $104.1 million in 2021, then climbed by 4.32% to $108.6 million in 2022, then increased by 24.23% to $135.0 million in 2023, then soared by 76.33% to $238.0 million in 2024.